Corporate Medical Policy

Genetic Testing for Adolescent Idiopathic Scoliosis AHS – M2058

File Name: genetic_testing_for_adolescent_idiopathic_scoliosis
Origination: 1/1/2019
Last CAP Review: 2/2020
Next CAP Review: 2/2021
Last Review: 2/2020

Description of Procedure or Service

Scoliosis is a disorder with abnormal rotation and curvature of the spine. In most cases, the cause is idiopathic. Adolescent Idiopathic Scoliosis (AIS) typically occurs after the age of 10, and the disease tends to run in families. Most individuals with scoliosis do not suffer from progression of the curvature, and treatment is needed only for a small percentage of patients (Scherl, 2018).

Genetic markers have been identified related to AIS. The ScoliScore™ Test is the first clinically validated genetic test for AIS.

***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician.

Policy

Genetic testing for adolescent idiopathic scoliosis is considered investigational. BCBSNC does not provide coverage for investigational services or procedures.

Benefits Application

This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore, member benefit language should be reviewed before applying the terms of this medical policy.

When genetic testing for Adolescent Idiopathic Scoliosis is covered

Not applicable

When genetic testing for Adolescent Idiopathic Scoliosis is not covered

DNA based prognostic testing for adolescent idiopathic scoliosis is considered investigational. BCBSNC does not cover investigational services or procedures.

Policy Guidelines

Literature review

AIS is the most common spinal deformity, affecting between 2-3% of children in the United States (Grauers, Einarsdottir, & Gerdhem, 2016). However, only 10% of adolescents with AIS progress to more severe curvature requiring treatment. Although males and females are affected equally, females are significantly more likely to have curve progression (Scherl, 2018).
The etiology of AIS is uncertain, but a genetic contribution is suggested by familial inheritance (Simony, Carreon, Hjmark, Kyvik, & Andersen, 2016). Increased levels of calmodulin in platelets and an asymmetrical distribution of calmodulin in paraspinal muscles (Acaroglu, Akel, Alanay, Yazici, & Marcucio, 2009), uncoordinated growth of the vertebral bodies in relation to the dorsal elements (Guo, Chau, Chan, & Cheng, 2003), higher growth velocity during puberty (Cheung et al., 2006), and high levels of cartilage oligomeric matrix protein (Gerdhem et al., 2015), have all been investigated.

Several genetic candidates have also been identified. Takahashi et al (2011) performed a large GWAS which found an association with a variant downstream of LBX1. Kou et al (2013) identified GPR126 mutation in a large Japanese GWAS. GPR126 was found to be highly expressed in cartilage and cause delayed ossification in zebrafish. Bashal et al (2014) completed exome sequencing for three members of a multigenerational family with idiopathic scoliosis, resulting in the identification of a variant in the HSPG2 gene as a potential contributor to the phenotype. Buchan et al (2014) used genome-wide rare variant burden analysis using exome sequence data, to identify fibrillin-1 (FBN1) as the most significantly associated gene with AIS, and scoliosis severity, suggesting that rare variants may be useful as predictors of curve progression. Ogura et al (2015) identified a variant of BNC2, overexpression of which resulted in body curvature in zebrafish in a dose dependent manner.

Haller et al (2016) analyzed exome sequence data of 391 severe AIS cases and 843 controls of European ancestry using a pathway burden analysis. Novel variants in musculoskeletal collagen were found in 32% (126/391) of AIS cases compared to 17% of the control cases (146/843). The authors concluded that the AIS cases “harbor mainly non-glycine missense mutations” but noted that the genetic basis for AIS was complex with a polygenic burden of rare variants (Haller et al., 2016).

Proprietary tests, such as ScoliScore, assess the genetic bases for AIS. ScoliScore was developed by the Virginia Spine Institute and intended for the prediction of the likelihood of curve progression. This test is noted to be appropriate for Caucasian patients ages 9-13 with a mild to moderate curve. 53 genetic markers are evaluated to determine the risk of progression, and these markers are combined (along with the Cobb angle) into a risk score from 1-200. The manufacturers state this test has a 99% negative predictive value for risk of progression (VSI, 2019).

**Clinical Validity and Utility**

Determination of which spinal curvature will progress is difficult. Prognostic testing for AIS has the potential to reduce psychological trauma, serial exposure to diagnostic radiation, unnecessary treatments, and direct and indirect costs-of-care related to scoliosis monitoring in low-risk patients.

Ward et al (2010) used logistic regression to develop and validate an algorithm to predict spinal curve progression incorporating genotypes for 53 single nucleotide polymorphisms (SNPs) and the patient’s presenting spinal curve, marketed as ScoliScore. 277 low risk females, 257 higher risk females, and 163 high risk males were sequenced and assessed using the ScoliScore algorithm. The risk model of the algorithm was standardized to identify 75% of patients as low-risk (<1% risk of progressing to a surgical curve), 24% as intermediate-risk, and 1% as high-risk. The cutoff scores were listed as <41 for low-risk, 50 for intermediate risk, and 180 for high risk. Low-risk scores had negative predictive values of 100% for the low-risk population, 99% for the higher risk females, and 97% for the high-risk males (Ward et al., 2010).

Although initial results were significant, the association of these variants to progression of scoliosis has not been replicated in either a Japanese or a French-Canadian cohort (Ogura et al., 2013; Tang et al., 2015). Ogura et al assessed the frequency of the 53 SNPs in a 600-sample progression group and a 1114-sample nonprogression group and did not find any difference in risk allele frequency between
Genetic Testing for Adolescent Idiopathic Scoliosis AHS – M2058

The replication association study by Tang et al to determine whether the 53 single nucleotide polymorphisms (SNPs) that were previously associated with spinal deformity progression in an American Caucasian cohort are similarly associated in French-Canadian population found that none of the SNPs used in ScoliScore were associated with adolescent idiopathic scoliosis curve progression or curve occurrence in French-Canadian population. No difference in risk allele frequencies between the severe and nonsevere groups was observed, as well as no difference between the severe and control groups (Tang et al., 2015).

Roye et al (2012) compared the risk stratification between ScoliScore and traditional clinical estimates to determine whether ScoliScore provides unique information. The study showed that clinical assessment classified more patients as high-risk (47 versus 9 percent), and ScoliScore categorized more patients as low risk (36 versus 2 percent). The authors found a positive correlation of $r = 0.581$ between the ScoliScore and the Cobb angle. The authors concluded that ScoliScore provides unique information to traditional clinical predictors of curve progression.

Roye et al (2015) conducted a dual-center retrospective cohort study of 126 Caucasian patients with AIS and Cobb angle between 10 and 25° to determine if the ScoliScore effectively predicted the risk of curve progression in patients with mild and moderate adolescent idiopathic scoliosis. The study concluded that ScoliScore results did not differ between patients with and without curve progression, and the negative and positive predictive values (0.87 and 0.27 respectively) were lower in the study than in the previously published validation study by the developers of the test. The ScoliScore of the patients with curve progression was a mean of 107 and standard deviation of 55 points, and the ScoliScore of the patients without the curve progression was a mean of 102 and standard deviation of 62 points (Roye et al., 2015).

**Applicable Federal Regulations**

The ScoliScore™ AIS (adolescent idiopathic scoliosis) prognostic DNA-based test (Axial Biotech, Salt Lake City, Utah) is considered a laboratory developed test (LDT); developed, validated and performed by individual laboratories.

Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA ’88). As an LDT, the U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use.

**Guidelines and Recommendations**

**International Scientific Society on Scoliosis Orthopaedic and Rehabilitation Treatment (SOSORT)**

SOSORT released revised evidence-based guidelines on conservative treatment of idiopathic scoliosis (Negrini et al., 2018) align the guidelines with the new scientific evidence to assure faster knowledge transfer into clinical practice. They state, “Recently developed genetic assessment, with 53 identified loci, can now help predict the risk of IS progression. The determination of the polymorphism of selected genes is meant to facilitate the assignment of a patient to a progressive or stable group. Unfortunately, the data originating from one population often are not confirmed in replication studies involving other populations. A prognostic genetic test, known as ScoliScore, has also been developed. Although these initial results have been promising, their generalizability is still uncertain (Negrini et al., 2018).”
Genetic Testing for Adolescent Idiopathic Scoliosis AHS – M2058

School screening programs are recommended for the early diagnosis of idiopathic scoliosis using the Scoliometer during trunk forward bend (Adam’s test) and 5° and 7° of angle of trunk rotation should be used as criteria for referral.

Screening is also recommended every time pediatricians, general practitioners and sports physicians evaluate children aged from 8 to 15 years (Negrini et al., 2018).

**U.S. Preventive Services Task Force (USPSTF)**
The USPSTF issued an updated recommendation (Grossman et al., 2018) that the current evidence is insufficient to assess the balance of benefits and harms of screening for adolescent idiopathic scoliosis in children and adolescents aged 10 to 18 years. No USPSTF recommendations for DNA-based testing for AIS were identified.

**American Academy of Family Physicians (AAFP)**
The AAFP published a clinical preventative service recommendation (2018) which states that “The AAFP supports the U.S. Preventive Services Task Force (USPSTF) clinical preventive service recommendation on this topic.”

**The Scoliosis Research Society (SRS), American Academy of Orthopaedic Surgeons (AAOS), Pediatric Orthopaedic Society of North America (POSNA), and American Academy of Pediatrics (AAP)**
The AAOS, SRS, POSNA, and AAP issued a statement (Hresko, Talwalkar, & Schwend, 2016) which states:

“The AAOS, SRS, POSNA, and AAP believe that there are documented benefits of earlier detection and non-operative management of AIS, earlier identification of severe deformities that are surgically treated, and incorporation of screening of children for AIS by knowledgeable health care providers as a part of their care... AAOS, SRS, POSNA, and AAP believe that screening examinations for spine deformity should be part of the medical home preventive services visit for females at age 10 and 12 years, and males once at age 13 or 14 years.”

**United Kingdom National Screening Committee (UK NSC, 2016)**
The UK NSC recommends against screening for AIS as it is “unclear whether treating people found through screening is better than waiting for symptoms to develop” and because there is no cutoff of the forward bend test where treatment is necessary (UKNSC, 2016).

**Billing/Coding/Physician Documentation Information**

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at www.bcbsnc.com. They are listed in the Category Search on the Medical Policy search page.

**Applicable codes:** 0004M

BCBSNC may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful, but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included.

**Scientific Background and Reference Sources**

AAFP. (2018). Scoliosis - Clinical Preventive Service Recommendation. from @aafp
https://www.aafp.org/patient-care/clinical-recommendations/all/scoliosis.html
Genetic Testing for Adolescent Idiopathic Scoliosis AHS – M2058


Genetic Testing for Adolescent Idiopathic Scoliosis AHS – M2058


Genetic Testing for Adolescent Idiopathic Scoliosis AHS – M2058

**Policy Implementation/Update Information**

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/1/19</td>
<td>New policy developed. BCBSNC will not provide coverage for genetic testing for adolescent idiopathic scoliosis because it is considered to be investigational. BCBSNC does not provide coverage for investigational services. Medical Director review 1/1/2019 for effective date 4/1/2019. (sk)</td>
</tr>
<tr>
<td>9/10/19</td>
<td>Added code 0004M back to policy. Code was removed erroneously on 8/27/19. (sk)</td>
</tr>
<tr>
<td>10/29/19</td>
<td>No changes to policy. (hb)</td>
</tr>
</tbody>
</table>

Medical policy is not an authorization, certification, explanation of benefits or a contract. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the group contract and subscriber certificate that is in effect at the time services are rendered. This document is solely provided for informational purposes only and is based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. Medical practices and knowledge are constantly changing and BCBSNC reserves the right to review and revise its medical policies periodically.